within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EK02_Cediranib;

model Cediranib
  extends Pharmacolibrary.Drugs.ATC.L.L01EK02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01EK02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Cediranib is an orally available small-molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor (VEGF) receptors. It was developed primarily for its anti-angiogenic properties, targeting tumor blood vessel growth in various cancers. Cediranib has been investigated in clinical trials for malignancies such as ovarian, lung, and colorectal cancers, but as of 2024, it is not approved for routine clinical use by major regulatory agencies.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult cancer patients (various solid tumors) after single and multiple oral doses of cediranib.</p><h4>References</h4><ol><li><p>Tang, W, et al., &amp; Masson, E (2017). Clinical Pharmacokinetics and Pharmacodynamics of Cediranib. <i>Clinical pharmacokinetics</i> 56(7) 689–702. DOI:<a href=\"https://doi.org/10.1007/s40262-016-0488-y\">10.1007/s40262-016-0488-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27943222/\">https://pubmed.ncbi.nlm.nih.gov/27943222</a></p></li><li><p>Lassen, U, et al., &amp; Sawyer, MB (2013). Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours. <i>Cancer chemotherapy and pharmacology</i> 71(2) 543–549. DOI:<a href=\"https://doi.org/10.1007/s00280-012-2038-0\">10.1007/s00280-012-2038-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23196640/\">https://pubmed.ncbi.nlm.nih.gov/23196640</a></p></li><li><p>Trarbach, T, et al., &amp; Drevs, J (2012). Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours. <i>Investigational new drugs</i> 30(5) 1962–1971. DOI:<a href=\"https://doi.org/10.1007/s10637-011-9754-x\">10.1007/s10637-011-9754-x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21989836/\">https://pubmed.ncbi.nlm.nih.gov/21989836</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Cediranib;
